Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 3/20 | 0.50 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | DUT | P33316 | 4/20 | 0.33 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.33 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.33 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.33 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7984568 | 0.81 | CRBN (0.45) | CRBNDDB1PKML3MBTL1ALDH1A1 | |
| SCHEMBL28242393 | 0.80 | CRBN (0.54) | CRBNDDB1PKML3MBTL1ALDH1A1 | |
| SCHEMBL7204552 | 0.80 | CRBN (0.48) | CRBNDDB1PKML3MBTL1ALDH1A1 | |
| SCHEMBL7715133 | 0.78 | CRBN (0.47) | CRBNDDB1PKML3MBTL1ALDH1A1 | |
| SCHEMBL8988103 | 0.78 | CRBN (0.47) | CRBNDDB1PKML3MBTL1ALDH1A1 | |
| SCHEMBL7715134 | 0.78 | CRBN (0.47) | CRBNDDB1PKML3MBTL1ALDH1A1 | |
| SCHEMBL10694738 | 0.78 | CRBN (0.47) | CRBNDDB1PKML3MBTL1ALDH1A1 | |
| SCHEMBL3414870 | 0.78 | CRBN (0.47) | CRBNDDB1PKML3MBTL1ALDH1A1 | |
| SCHEMBL19348252 | 0.74 | CRBN (0.43) | CRBNDDB1L3MBTL1ALDH1A1LMNA | |
| SCHEMBL5705360 | 0.70 | CRBN (0.47) | CRBNDDB1PKML3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115181147-B | Preparation method of C4 '-trifluoromethylthio modified nucleoside and C4' -trifluoromethylthio modified nucleic acid | 南开大学 | 2024-04-02 | — | — | CN | claimed |
| CN-117512078-A | Single primer to double primer amplicon conversion | 西格马-奥尔德里奇有限责任公司 | 2024-02-06 | — | — | CN | claimed |
| CN-109804083-B | Single primer to double primer amplicon conversion | 西格马-奥尔德里奇有限责任公司 | 2023-11-03 | — | — | CN | claimed |
| US-20220315972-A1 | SINGLE PRIMER TO DUAL PRIMER AMPLICON SWITCHING | SIGMA ALDRICH CO LLC (US) | 2022-10-06 | — | — | US | claimed |
| US-11390913-B2 | Single primer to dual primer amplicon switching | SIGMA-ALDRICH CO. LLC (US) | 2022-07-19 | — | — | US | claimed |
| US-12595506-B2 | Compositions and methods for analyzing modified nucleotides | NEW ENGLAND BIOLABS, INC. (US) | 2026-04-07 | — | — | US | disclosed |
| US-12571024-B2 | Methods and compositions relating to covalently closed nucleic acids | Twist Bioscience Corporation (US) | 2026-03-10 | — | — | US | disclosed |
| EP-3971201-B1 | CELL CULTURING SCAFFOLD MATERIAL AND CELL CULTURING CONTAINER | SEKISUI CHEMICAL CO LTD (JP) | 2026-01-28 | — | — | EP | disclosed |
| EP-3971200-B1 | CELL CULTURING SCAFFOLDING MATERIAL AND CELL CULTURING VESSEL | SEKISUI CHEMICAL CO LTD (JP) | 2026-01-21 | — | — | EP | disclosed |
| EP-4664304-A2 | NUCLEIC ACID BASED DATA STORAGE | Atlas Data Storage, Inc. (US) | 2025-12-17 | — | — | EP | disclosed |
| US-12460167-B2 | Scaffold material for cell culture and cell culture container | SEKISUI CHEMICAL CO., LTD. (JP) | 2025-11-04 | — | — | US | disclosed |
| EP-3516528-B1 | NUCLEIC ACID BASED DATA STORAGE | ATLAS DATA STORAGE INC (US) | 2025-10-15 | — | — | EP | disclosed |
| US-11263354-B2 | Nucleic acid based data storage | Twist Bioscience Corporation (US) | 2022-03-01 | — | — | US | disclosed |
| EP-3950925-A1 | CELL CULTURE SCAFFOLD MATERIAL, CELL CULTURE VESSEL, CELL CULTURE CARRIER, CELL CULTURE FIBER AND CELL CULTURE METHOD | SEKISUI CHEMICAL CO., LTD. (JP) | 2022-02-09 | — | — | EP | disclosed |
| WO-2011132017-A1 | PYRIDO[3,4-D]PYRIMIDINYL ACETAMIDE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2011-10-27 | — | — | WO | disclosed |
| WO-2010125469-A1 | PYRIMIDINEDIONE-FUSED HETEROCYCLIC COMPOUNDS AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2010-11-04 | — | — | WO | disclosed |
| US-7534796-B2 | Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor | WYETH (US) | 2009-05-19 | — | — | US | disclosed |
| WO-2006135763-A2 | INHIBITORS OF DNA REPAIR ENZYMES AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY (US) | 2006-12-21 | — | — | WO | disclosed |
| US-20060189617-A1 | Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor | WYETH (US) | 2006-08-24 | — | — | US | disclosed |
| WO-2002048320-A2 | CRYSTAL STRUCTURES OF RETAINING GLYCOSYLTRANSFERASES | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2002-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12571024-B2 | Methods and compositions relating to covalently closed nucleic acids | UNG, OGG1, RNGTT | CRBN 3348/4885DDB1 217/4885PKM 3768/4885 |
| US-20060189617-A1 | Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor | GNRHR, PRLHR, FSHR | CRBN 1958/4885DDB1 3093/4885PKM 3753/4885 |
| US-12595506-B2 | Compositions and methods for analyzing modified nucleotides | UNG, RNMT, NT5C3B | CRBN 2952/4885DDB1 480/4885PKM 816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.